161 related articles for article (PubMed ID: 26888024)
1. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
2. The safety of incretin based drugs.
Montori VM
BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
[No Abstract] [Full Text] [Related]
3. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
4. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
Schectman J
Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
[No Abstract] [Full Text] [Related]
5. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Jermendy G
Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
[TBL] [Abstract][Full Text] [Related]
7. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
[No Abstract] [Full Text] [Related]
8. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
9. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
[No Abstract] [Full Text] [Related]
10. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
12. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
Berg EG
Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
[No Abstract] [Full Text] [Related]
13. Incretin-based drugs and the risk of congestive heart failure.
Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
[TBL] [Abstract][Full Text] [Related]
14. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections.
Rizvi AA; Linhart A; Vrablik M; Liberopoulos E; Rizzo M
Expert Opin Drug Saf; 2022 Mar; 21(3):291-293. PubMed ID: 35188012
[No Abstract] [Full Text] [Related]
15. No increased heart failure risk is reported with DPP-4 inhibitors.
Wise J
BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
[No Abstract] [Full Text] [Related]
16. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
Patel T; Tesfaldet B; Gandotra C;
BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
[No Abstract] [Full Text] [Related]
17. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
[No Abstract] [Full Text] [Related]
18. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
19. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
20. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
